The current study was designed to investigate the impact of KCNQ1 genetic polymorphism on the efficacy of repaglinide and furthermore to identify the potential mechanism of action in patients with type 2 diabetes. The gene discussed is KCNQ1; the disease is type 2 diabetes mellitus.